Skip to main content
SpringerLink
Log in

On a 5-year-old girl with multiple sclerosis treated with natalizumab

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Data availability

The data that support the findings of this case report are fully available from the corresponding author, [S.S.], upon reasonable request.

References

  1. Gorman MP, Healy BC, Polgar-Turcsany M, Chitnis T (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66:54–59

    Article  PubMed  Google Scholar 

  2. Baroncini D, Simone M, Iaffaldano P, Italian MS, registry, et al (2021) Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol 78:726–735

    Article  PubMed  Google Scholar 

  3. Ghezzi A, Banwell B, Boyko A et al (2010) The management of multiple sclerosis in children: a European view. Mult Scler 16:1258–1267

    Article  PubMed  Google Scholar 

  4. Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173

    Article  PubMed  Google Scholar 

  5. Baroncini D, Ghezzi A, Guaschino C et al (2022) MS Study Group of the Italian Neurological Society. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurol Sci 43:6415–6423

    Article  PubMed  Google Scholar 

  6. Kornek B, Aboul-Enein F, Rostasy K et al (2013) Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol 70:469–475

    Article  PubMed  Google Scholar 

  7. Margoni M, Rinaldi F, Riccardi A et al (2020) No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab. J Neurol 267:100–105

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the patient’s parents for allowing this report and signing the informed consent.

Author information

Authors and Affiliations

  1. Unit of Child Neuropsychiatry, Department of Medicine, Surgery and Pharmacy, University Hospital of Sassari, University of Sassari, Viale San Pietro 42, 07100, Sassari, Italy

    Stefano Sotgiu, Arianna Nieddu, Arianna Madrau & Alessandra Carta

  2. Pediatric Neurology and Epileptology Unit, Pediatric Department, ARNAS Brotzu, Cagliari, Italy

    Dario Pruna

  3. Multiple Sclerosis Centre, Department of Medicine, Surgery and Pharmacy, University Hospital of Sassari, Sassari, Italy

    Ignazio Roberto Zarbo

Authors
  1. Stefano Sotgiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arianna Nieddu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dario Pruna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arianna Madrau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ignazio Roberto Zarbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alessandra Carta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Sotgiu.

Ethics declarations

Ethical approval

The patient’s parents provided written informed consent. The study was performed in agreement with the Declaration of Helsinki.

Conflict of interest

IRZ acted as an Advisory Board member of, and received funding and honoraria for speaking or consultation fees from Merck-Serono, Teva, Sanofi-Genzyme, Biogen, Genzyme, Novartis, Roche, Admirall. DP has received funding for traveling from Eisai, Jazz Pharmaceutical, Ecupharma, Neuraxpharm and UCBSS. SS, AN, AM and CA report no disclosures.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sotgiu, S., Nieddu, A., Pruna, D. et al. On a 5-year-old girl with multiple sclerosis treated with natalizumab. Neurol Sci 44, 2963–2965 (2023). https://doi.org/10.1007/s10072-023-06780-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-023-06780-2

Search

Navigation